AstraZeneca, Daiichi Sankyo and breast cancer

After Tough 2024, AstraZeneca/Daiichi Sankyo Push Enters Key Period
Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks in 2024.
AstraZeneca, Daiichi Sankyo win first U.S. approval for key cancer drug
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the closely watched treatment.
AstraZeneca And Daiichi Sankyo's Datroway Gets US Approval For Metastatic HR+ Breast Cancer
British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab
AstraZeneca/Daiichi Sankyo’s Datroway granted FDA approval in breast cancer
AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug Administration (FDA) to treat a subset of breast cancer patients.
Daiichi Sankyo rises most in five months on cancer drug approval
Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a milestone in the company’s efforts to turn it into a widely used blockbuster. The stock climbed as much as 8% in early morning trading in Tokyo on Monday, the largest intraday gain since Aug. 6.
AstraZeneca-Daiichi Sankyo Datroway gets USFDA nod for previously treated Metastatic HR Positive, HER2 Negative Breast Cancer
Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone
Datroway, 2nd ADC from AstraZeneca-Daiichi collab, wins first FDA nod in breast cancer
Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the U.S. regulatory finish line. | AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate,
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
AstraZeneca and Daiichi Sankyo win U.S. approval for breast cancer drug
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain genetic signature.
Daiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer Drug
Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday after rising as much as 9.
Pharm Exec16h
FDA Approves AstraZeneca, Daiichi Sankyo’s Datroway for Previously Untreated Unresectable, Metastatic HR-Positive, HER2-Negative Breast Cancer
Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the risk of disease progression or death in patients with previously ...
Hosted on MSN17h
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...
pharmaphorum2d
AZ, Daiichi get FDA nod for Dato-DXd in breast cancer
The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...